Budget Agreement. The Institution, Investigator and Covance have each reviewed and approved the budget attached which lists the amounts incurred for completed visits during the course of the Study. This budget is approved for maximum payment of 115 585 EUR (representing 5 evaluable patients at 23 117 EUR per patient, each completing the entire Study course according to the Protocol). This payment per patient also includes any task that is required of the Investigator and Institution by ICH-GCP e.g. administrative tasks. The attached budget checklist will be the basis for calculating and reimbursing all Study-related costs. It is understood and agreed that no reimbursement will be provided for patients who are randomised into the Study and do not conform to the Protocol's inclusion and exclusion criteria or for whom serious deviations from the Protocol are made. It is agreed that reimbursement for eligible patients who do not complete all visits in the Study will be pro-rated according to the budget checklist. Interim payments will be made in regular instalments following the randomisation of the first patient into the Study and will be based upon the number of visits completed by patient at the payment date. Institution and/or Investigator agree to submit a final invoice to Covance within forty five (45) days of completion of the Study. Final payment will be made after Covance has received and thoroughly reviewed all the Case Report Forms and all appropriate Data Clarification Forms are duly signed by the Investigator. The total actual (pro-rated) costs will be determined and the final instalment will equal the total plus the additional payments if applicable less the total already paid. This payment schedule will be modified if it becomes apparent that the total number of patients accrued will fall short of or exceed (after mutual agreement with Covance) the anticipated 5 patients and that adherence to this schedule would result in substantial overpayment/underpayment to the Institution and/or Investigator.

Budget Agreement the applicant agrees that: 3.1 A project plan for the location will be developed and costed by Keep Britain Tidy following the site visit and agreed with team members prior to submitting to Camden Council for approval. All installations and supplier costs required to deliver the project must fall within the £800 budget, however team members can choose to contribute their own resources to the project on top of this if they wish (this includes tools, materials, skills and expertise but excludes monetary contributions); 3.2 Keep Britain Tidy will be responsible for allocating and administering funds, within the agreed budget, based on consultation with the applicant, their group and subject to the project plan being signed off by Camden Council.

Budget Agreement. The Parties agree that on or before the date this MOU is executed the Department, ACOC and the Executive Director shall enter into a letter agreement which details the approved line item budget and priorities for the uses of funds for the Pilot Program (the “Budget Agreement”). The amounts set forth in the Budget Agreement will be a cap on payment from the Pilot Program for such costs, which may not be exceeded absent the Executive Director’s prior approval of an amendment to the Budget Agreement in her sole discretion. The Budget Agreement will include more detailed estimates of the costs to fulfill the donor recognition (e.g. design, fabrication and installation of plaques) (“Gift Fulfillment Costs”) as well as ACOC’s costs to promote and administer the opportunity (“Approved Program Costs”). Approved Program Costs shall include $35,000 expended by ACOC in furtherance of the Pilot Program prior to the Effective Date. The Budget Agreement will also establish a hierarchy of uses of the receipts of the Pilot Program, net of the Gift Fulfillment Costs and the Approved Program Costs (“Net Program Revenues”). The Budget Agreement will also set forth Donor Recognition Agreement term limitations for each type of opportunity site as established by the Executive Director in her sole discretion after consultation with ACOC and the Department.

Budget Agreement. Provided that the Development Committee and the Steering Committee are able to establish and approve a Development Plan and Budget for the upcoming year on or before [c.i.] of any particular year (excluding 1999), or a dispute arose which was resolved thereafter by the Chief Executive Officer of DUSA and senior executive officer designated by Schering in accordance with Section 2.1.3 above, development priorities shall be in accordance with such Development Plan and Budget and Section 3.1.4 above.

Budget Agreement. ‌ 3.1 The Director should present the proposed budget for the following year to the Advisory Committee for agreement, plus the indicative budgets for the following two years for information, at a meeting of the Advisory Committee to be held during October of each year.

Budget Agreement. A few hours ago, as expected, the Legislature passed a raft of bills that together comprise the $300 billion budget agreement reached over the weekend between the Administration, the Senate, and the Assembly. AB 178 comprehensively amends the Budget Bill (SB 154) passed two weeks ago and signed by the Governor on Monday. We expect the Governor to sign the amended Budget Bill and the many trailer bills by Friday. The agreement includes a number of high-profile items, such as: • $9.5 billion in direct refunds to income tax filers with incomes up to $250,000 for single filers and $500,000 for joint filers. • $47 billion for infrastructure over four years, including:

Related to Budget Agreement

One Agreement This Agreement and any related security or other agreements required by this Agreement, collectively: (a) represent the sum of the understandings and agreements between the Bank and the Borrower concerning this credit; (b) replace any prior oral or written agreements between the Bank and the Borrower concerning this credit; and (c) are intended by the Bank and the Borrower as the final, complete and exclusive statement of the terms agreed to by them. In the event of any conflict between this Agreement and any other agreements required by this Agreement, this Agreement will prevail.
COMPLETE AGREEMENT; AMENDMENTS This Agreement is the complete and exclusive agreement between the parties with respect to the subject matter contemplated thereby. No modifications to this Agreement shall be made or binding unless made in writing and signed by all parties to this Agreement.
Complete Agreement; Amendment This Agreement constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior or contemporaneous agreements in regard thereto. This Agreement cannot be modified except by an agreement in writing signed by both parties and specifically referring to this Agreement.
Cooperation Agreement If a Cooperating Institution is appointed, the Fund shall enter into a Cooperation Agreement with the Cooperating Institution setting forth the terms and conditions of its appointment.
Transition Agreement In the event of termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos pursuant to Section 12.2.1, or with respect to one (1) or more countries or other jurisdictions by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i), Galapagos and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Galapagos will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Galapagos as reasonably necessary for Galapagos to exercise the licenses granted pursuant to Sections 12.6 or 12.7 after termination of this Agreement (in its entirety or with respect to one (1) or more countries or other jurisdictions, as applicable) as and to the extent set forth in this Article 12. For clarity, AbbVie shall not be required to Manufacture or have Manufactured the Molecules or Products by or on behalf of Galapagos as part of the Transition Agreement. 12.8.1 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie or its Affiliates or Sublicensees and in its/their name applicable to the Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (iv) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of pre-clinical Development activities, Clinical Studies or Manufacturing activities for the Products, including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i) (but not in the case of any termination of this Agreement in its entirety), AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Approvals owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, which Regulatory Approvals are solely applicable to the relevant country or jurisdiction and the Products that are the subject of an exclusive license grant in Section 12.7, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such relevant country or jurisdiction; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Products in the Territory, Develop Molecules or Products in support of such Commercialization, or Manufacture Molecules or Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Galapagos a right of reference to all Regulatory Documentation then owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, and which Regulatory Documentation is not transferred to Galapagos pursuant to clause (i) above, and is necessary or reasonably useful for Galapagos, any of its Affiliates or sublicensees to Develop or Commercialize in the terminated country or jurisdiction the Product(s) that are the subject of the license grant in Section 12.7 as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such terminated country or jurisdiction; (iv) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies specific to such terminated country(ies) being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (v) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of Clinical Studies specific to such terminated country(ies), including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party.
Arrangement Agreement This Plan of Arrangement is made pursuant to, and is subject to the provisions of, the Arrangement Agreement, except in respect of the sequence of the steps comprising the Arrangement, which shall occur in the order set forth herein.
Acquisition Agreements If the Equipment is subject to any Acquisition Agreement, Lessee, as part of this lease, transfers and assigns to Lessor all of its rights, but none of its obligations (except for Lessee's obligation to pay for the Equipment conditioned upon Lessee's acceptance in accordance with Paragraph 6), in and to the Acquisition Agreement, including but not limited to the right to take title to the Equipment. Lessee shall indemnify and hold Lessor harmless in accordance with Paragraph 19 from any liability resulting from any Acquisition Agreement as well as liabilities resulting from any Acquisition Agreement Lessor is required to enter into on behalf of Lessee or with Lessee for purposes of this lease.
EFFECTIVE DATE; TERM OF AGREEMENT This Agreement shall become effective as of January 29, 2010 (the “Effective Date”). Upon effectiveness of this Agreement on the Effective Date, the Employment Agreement between the Company and the Executive dated as of September 8, 2006 (as amended, the “Prior Agreement”) shall terminate and be of no further force and effect. Subject to earlier termination as provided herein, Executive’s employment hereunder shall continue on the terms provided herein until February 2, 2013 (the “End Date”). The period of Executive’s employment by the Company from and after the Effective Date, whether under this Agreement or otherwise, is referred to in this Agreement as the “Employment Period,” it being understood that nothing in this Agreement shall be construed as entitling Executive to continuation of his employment beyond the End Date and that any such continuation shall be subject to the agreement of the parties. This Agreement is intended to comply with the applicable requirements of Section 409A and shall be construed accordingly.
Reimbursement Agreement The Sponsor entered into an Expense Reimbursement Agreement (“Reimbursement Agreement”) substantially in the form annexed as an exhibit to the Registration Statement pursuant to which the Sponsor has committed to fund the Company up to $1,750,000 for the Company’s expenses relating to investigating and selecting a target business and other working capital requirements prior to an initial Business Combination.
Term of Agreement; Amendment This Agreement shall become effective as of the date first written above and will continue in effect for a period of three (3) years. This Agreement may be terminated by either party upon giving 90 days prior written notice to the other party or such shorter period as is mutually agreed upon by the parties. Notwithstanding the foregoing, this Agreement may be terminated by any party upon the breach of the other party of any material term of this Agreement if such breach is not cured within 15 days of notice of such breach to the breaching party. This Agreement may not be amended or modified in any manner except by written agreement executed by USBFS and the Trust, and authorized or approved by the Board of Trustees.

Budget Agreement Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to Budget Agreement